Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. 1998

J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
Division of Biomedical Sciences, Randall Institute, King's College, London, United Kingdom.

Antiherpes therapies are principally targeted at viral thymidine kinases and utilize nucleoside analogs, the triphosphates of which are inhibitors of viral DNA polymerase or result in toxic effects when incorporated into DNA. The most frequently used drug, aciclovir (Zovirax), is a relatively poor substrate for thymidine kinase and high-resolution structural information on drugs and other molecules binding to the target is therefore important for the design of novel and more potent chemotherapy, both in antiherpes treatment and in gene therapy systems where thymidine kinase is expressed. Here, we report for the first time the binary complexes of HSV-1 thymidine kinase (TK) with the drug molecules aciclovir and penciclovir, determined by X-ray crystallography at 2.37 A resolution. Moreover, from new data at 2.14 A resolution, the refined structure of the complex of TK with its substrate deoxythymidine (R = 0.209 for 96% of all data) now reveals much detail concerning substrate and solvent interactions with the enzyme. Structures of the complexes of TK with four halogen-containing substrate analogs have also been solved, to resolutions better than 2.4 A. The various TK inhibitors broadly fall into three groups which together probe the space of the enzyme active site in a manner that no one molecule does alone, so giving a composite picture of active site interactions that can be exploited in the design of novel compounds.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013937 Thymidine Kinase An enzyme that catalyzes the conversion of ATP and thymidine to ADP and thymidine 5'-phosphate. Deoxyuridine can also act as an acceptor and dGTP as a donor. (From Enzyme Nomenclature, 1992) EC 2.7.1.21. Deoxythymidine Kinase,Deoxypyrimidine Kinase,Kinase, Deoxypyrimidine,Kinase, Deoxythymidine,Kinase, Thymidine
D018259 Herpesvirus 1, Human The type species of SIMPLEXVIRUS causing most forms of non-genital herpes simplex in humans. Primary infection occurs mainly in infants and young children and then the virus becomes latent in the dorsal root ganglion. It then is periodically reactivated throughout life causing mostly benign conditions. HSV-1,Herpes Simplex Virus 1,HHV-1,Herpes Simplex Virus Type 1,Herpesvirus 1 (alpha), Human,Human Herpesvirus 1
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies

Related Publications

J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
December 2000, Proteins,
J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
June 1994, Nippon Ganka Gakkai zasshi,
J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
March 1999, Nucleosides & nucleotides,
J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
June 1993, Virus genes,
J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
October 1991, Journal of computer-aided molecular design,
J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
December 1982, The Journal of general virology,
J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
August 1994, The Biochemical journal,
J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
June 2002, Journal of virology,
J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
April 1989, The Journal of general virology,
J N Champness, and M S Bennett, and F Wien, and R Visse, and W C Summers, and P Herdewijn, and E de Clerq, and T Ostrowski, and R L Jarvest, and M R Sanderson
October 1992, Journal of medicinal chemistry,
Copied contents to your clipboard!